Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,163,556
  • Shares Outstanding, K 51,394
  • Annual Sales, $ 336,890 K
  • Annual Income, $ -87,940 K
  • EBIT $ -42 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.49
  • Price/Sales 10.51
  • Price/Cash Flow N/A
  • Price/Book 16.90

Options Overview Details

View History
  • Implied Volatility 43.43% (-1.01%)
  • Historical Volatility 39.08%
  • IV Percentile 29%
  • IV Rank 30.23%
  • IV High 70.14% on 04/10/25
  • IV Low 31.86% on 08/21/25
  • Expected Move (DTE 12) 5.74 (5.71%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 20
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 1,244
  • Open Int (30-Day) 1,105
  • Expected Range 94.73 to 106.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 6
  • High Estimate 0.19
  • Low Estimate -0.26
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +104.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.74 +30.92%
on 01/07/26
105.74 -4.98%
on 02/04/26
+24.01 (+31.40%)
since 01/06/26
3-Month
63.23 +58.89%
on 12/15/25
105.74 -4.98%
on 02/04/26
+32.75 (+48.36%)
since 11/06/25
52-Week
36.88 +172.42%
on 04/09/25
105.74 -4.98%
on 02/04/26
+49.24 (+96.12%)
since 02/06/25

Most Recent Stories

More News
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

- Authorization includes oral solution and tablet formulation to support flexible dosing

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

- Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum’s portfolio - Topline Phase 3 results expected...

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

- 2025 net product sales of approximately $520 million (preliminary and unaudited) exceed upper end of guidance - 2026 expected global net product sales of $630...

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday,...

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor,...

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock...

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with...

MIRM : 100.47 (+2.28%)
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Proof-of-concept study underway for investigational oral therapy in Fragile X syndrome; top-line data from Phase 2 expected in 2027

MIRM : 100.47 (+2.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 105.46
2nd Resistance Point 103.27
1st Resistance Point 101.87
Last Price 100.47
1st Support Level 98.28
2nd Support Level 96.09
3rd Support Level 94.69

See More

52-Week High 105.74
Last Price 100.47
Fibonacci 61.8% 79.44
Fibonacci 50% 71.31
Fibonacci 38.2% 63.18
52-Week Low 36.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar